Michael Brawer, MD

home / authors / michael-brawer-md

Articles

Dr. Brawer on the Results of the Prolaris Test for Patients Prostate Cancer

Dr. Brawer on the Results of the Prolaris Test for Patients Prostate Cancer

Michael Brawer, MD
September 6th 2017

Michael Brawer, MD, vice president of medical affairs, Myriad Genetic Laboratories, discusses the results of the Prolaris genetic test in predicting prostate cancer aggressiveness in African-American men.

Read More

Dr. Brawer on the Significance of the Prolaris Genetic Test for Prostate

Dr. Brawer on the Significance of the Prolaris Genetic Test for Prostate

Michael Brawer, MD
August 17th 2017

Michael Brawer, MD, vice president of medical affairs, Myriad Genetic Laboratories, discusses the significance of the Prolaris genetic test in predicting prostate cancer aggressiveness in African-American men.

Read More

Dr. Brawer on the Prolaris Genetic Test in Predicting Prostate Cancer Aggressiveness

Dr. Brawer on the Prolaris Genetic Test in Predicting Prostate Cancer Aggressiveness

Michael Brawer, MD
May 22nd 2017

Michael Brawer, MD, vice president of Medical Affairs, Myriad Genetic Laboratories, discusses the Prolaris genetic test in predicting prostate cancer aggressiveness in African-American men.

Read More

Dr. Brawer on Clinical Utility of CCP Test in Prostate Cancer

Dr. Brawer on Clinical Utility of CCP Test in Prostate Cancer

Michael Brawer, MD
May 17th 2015

Michael Brawer, MD, vice president of Medical Affairs, Myriad Genetic Laboratories, discusses the clinical utility of the cell cycle progression (CCP) test in personalizing prostate cancer treatment.

Read More

Dr. Brawer on Predicting Radical Prostatectomy Outcomes

Dr. Brawer on Predicting Radical Prostatectomy Outcomes

Michael Brawer, MD
July 22nd 2014

Michael Brawer, MD, vice president, Medical Affairs, Myriad Genetics, discusses a study that looked at predicting radical prostatectomy outcomes.

Read More

Latest Updated Articles

OncLive co-hosts Kristie L. Kahl and Andrew Svonavec highlight abstracts for medical oncologists to look out for at the upcoming ASH Annual Meeting in San Diego, with some additional tidbits to round out the main event.
Published: December 3rd 2024 | Updated: December 6th 2024
ASH 2024 Preview for Medical Oncologists: The Show and After Show
Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer